Back to search

Article

PRMT5 is a therapeutic target in choroidal neovascularization

2022-03-30

Abstract excerpt

Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients’ non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel therapeutic target for nvAMD. PRMT5 is a well-known epigenetic e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
772c31e0-9692-5fb7-9642-2732c2f9e30b
DOI
10.1101/2022.03.30.486275
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PRMT5 is a therapeutic target in choroidal neovascularizationDOI 10.1101/2022.03.30.486275
Select a neighboring publication to make it the new centre.